He is the chairman of Genitourinary Oncology Committee and have taken over as head of the "International Academic Network" division in September 2021.
Karim Fizazi is leading major studies in oncology: role of denosumab in the prevention of complications of bone metastases of prostate cancer, impact of chemotherapy combined with standard of care on relapse-free survival in patients with localized and high-risk prostate cancer (GETUG 12 study), new standard of care for young patients with severe testicular cancer (GETUG 13 study).
He published the results of the LATITUDE study in 2017 that changed the treatment of newly diagnosed patients with metastatic prostate cancer. He is leading the ARAMIS trial in high-risk non-metastatic castration-resistant prostate cancer.
Prof. Fizazi established the Prostate Cancer Consortium in Europe (PEACE) and leads the first two large European Phase III trials: PEACE-1 and PEACE-2.
Prof. Fizazi is Associate Editor of the European Journal of Cancer and has authored over 300 scientific publications.